Jove
Visualize
Contact Us

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Sarcomatoid Change In Combined Hepatocellular Carcinoma And Cholangiocarcinoma As A Poor Prognostic Factor.
  1. Home
  3. Sarcomatoid Change In Combined Hepatocellular Carcinoma And Cholangiocarcinoma As A Poor Prognostic Factor.

Related Experiment Video

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K

Sarcomatoid change in combined hepatocellular carcinoma and cholangiocarcinoma as a poor prognostic factor.

Suk Won Lee1, Milim Kim2, Sung Hyun Kim3

  • 1Department of General Surgery, Severance Hospital, Seoul, Korea.

Journal of Gastrointestinal Oncology
|September 16, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Sarcomatoid change in combined hepatocellular-cholangiocarcinoma (cHCC-CC) indicates a worse prognosis. This study confirms sarcomatoid change is a significant poor prognostic factor for resected cHCC-CC patients.

Keywords:
Combined hepatocellular-cholangiocarcinoma (cHCC-CC)hepatectomyprognosissarcomatoid changesurvival analysis

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection
07:22

Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection

Published on: April 11, 2025

102

Related Experiment Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection
07:22

Laparoscopic Left Hemihepatectomy Combined with Caudate Lobe Resection

Published on: April 11, 2025

102

Area of Science:

  • Hepatobiliary pathology
  • Surgical oncology
  • Cancer research

Background:

  • Sarcomatoid change, a rare epithelial malignancy feature, is observed across diverse organs.
  • Its impact on combined hepatocellular-cholangiocarcinoma (cHCC-CC) prognosis is largely unstudied due to rarity.
  • This study investigates the oncological significance of sarcomatoid change in cHCC-CC.

Purpose of the Study:

  • To determine the oncological impact of sarcomatoid change in patients with cHCC-CC.
  • To verify if sarcomatoid change is a poor prognostic factor in resected cHCC-CC.

Main Methods:

  • Retrospective review of 102 patients who underwent surgical resection for cHCC-CC (January 2006 - December 2020).
  • Calculation of hazard ratios (HR) for sarcomatoid change against known prognostic factors.
  • Comparative survival analysis between sarcomatoid change positive and negative groups.

    • Main Results:

    • Multivariate analysis identified sarcomatoid change as a poor prognostic factor for both disease-free survival (DFS; HR=3.84) and overall survival (OS; HR=3.94).
    • Patients with sarcomatoid change showed significantly worse DFS (4.0 vs. 23.0 months) and OS (19.0 vs. 85.0 months) compared to those without.
    • P-values for survival differences were <0.002, confirming statistical significance.

    Conclusions:

    • Sarcomatoid change is confirmed as a poor prognostic factor for resected combined hepatocellular-cholangiocarcinoma (cHCC-CC).
    • The presence of sarcomatoid change significantly impacts patient survival outcomes.
    • This finding aids in risk stratification and treatment planning for cHCC-CC.